Kaitlyn D’Onofrio

DocwireNews

Peficitinib was a safe and effective <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/treat-to-target-approach-needed-for-rheumatoid-arthritis/">treatment option</a> for patients with <a href="https://www.docwirenews.com/abstracts/rheumatology-abstracts/quality-improvement-for-rheumatoid-arthritis-care-results-from-a-focus-group/">rheumatoid arthritis</a> (RA) in a new study.RA treatment consists of disease-modifying antirheumatic drugs (<a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/do-outcomes-largely-differ-in-very-early-rheumatoid-arthritis-treated-with-first-line-etanercept-plus-methotrexate-versus-treat-to-target-methotrexate/">DMARDs</a>), often beginning with methotrexate; patients who do not respond to conventional DMARDs may receive biologic agents like tumor necrosis factor-alpha (TNF-&alpha;) inhibitors.&ldquo;The Janus kinase (JAK) family of non-receptor protein tyrosine kinases (JAK1, JAK2, JAK3, and tyrosine kinase 2 [TYK2]) plays a crucial role in multiple cytokine receptor signaling pathways and is a promising target for RA treatment in patients with insufficient response to DMARDs and biologic agents. JAK inhibitors available for the treatment of patients with RA include tofacitinib (a pan-JAK inhibitor approved in the USA, Europe, and Asia), baricitinib (a JAK1 and JAK2 selective inhibitor approved in the USA, Europe and Asia, and more recently peficitinib (ASP015K; approved in Japan),&rdquo; the study authors wrote.The present report was an interim analysis of a continuing study in RA patients who successfully completed 12-week phase 2b and 52-week phase 3 studies of peficitinib in Asia. Patients received one-daily oral peficitinib 100 mg or 50 mg; doses could be increased up to 150 mg or decreased up to 50 mg. Efficacy was assessed per American College of Rheumatology (ACR) response rates, ACR components, and disease activity score in 28 joints based on C-reactive protein (DAS28-CRP).<h2>Peficitinib Efficacy Persists Through Extension Study</h2>The analysis included data from 853 patients through May 2018. Patients had a mean peficitinib duration exposure of 22.7 months. Two-thirds of patients&rsquo; maximum dose was 100 mg. At week zero of the extension study, ACR20/50/70 response rates were 71.6%, 52.1%, and 34.7%, respectively; at the end of treatment, the rates were 78.9%, 61.4%, and 42.7%, respectively. The researchers observed improvements in both ACR components and DAS28-CRP from baselines of the previous studies; improvements persisted throughout the extension study. A total of 757 patients (89.8%) reported treatment-emergent adverse events (TEAEs), most of which were severity grade 1/2; the most common were nasopharyngitis (39.7%) and herpes zoster (11.7%). Fifty-five patients (6.5%) sustained drug-related TEAEs that resulted in permanent study drug discontinuation. The incidence rates per 100 patient-years of specific AEs were: serious infections, 2.3; herpes zoster-related disease, 6.8; and malignancies, 1.1. Regarding mortality, the researchers wrote, &ldquo;One death from diffuse large B cell lymphoma during the study and one death from uterine sarcoma after the study were considered probably and possibly related to study drug, respectively.&rdquo;The study was published in <a href="https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-020-2125-2">Arthritis Research &amp; Therapy</a>.The researchers concluded, &ldquo;Peficitinib administration for up to 6&thinsp;years was well tolerated and no new safety signals were identified. These results suggest that peficitinib may be an effective long-term treatment option for Asian patients with RA.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Study Assesses Safety, Efficacy of Peficitinib in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis

Peficitinib was a safe and effective treatment option for patients with rheumatoid arthritis (RA) in a new study. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe